Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hepatitis b breakthrough? new drug AHB-137 shows promise in Long-Term Follow-Up

NCT ID NCT07146100

Disease control Sponsor: Ausper Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 19, 2026 · Updated 4 times

Summary

This study checks if people with chronic hepatitis B who got better with the drug AHB-137 stay virus-free over time. About 200 adults who already responded to AHB-137 will be followed for years. The goal is to see if the virus stays undetectable and if liver health improves without needing more treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jan 2030

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who have previously participated in AHB-137 clinical trials

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Capable of giving informed consent. * Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study. Exclusion Criteria: * Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137. * Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis B

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    37 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Hefei, Anhui, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, China

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Chongqing, Chongqing Municipality, China

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Chongqing, Chongqing Municipality, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Fuzhou, Fujian, China

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Xiamen, Fujian, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Lanzhou, Gansu, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Foshan, Guangdong, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Guangzhou, Guangdong, China

  • AusperBio Investigational Site

    RECRUITING

    Guangzhou, Guangdong, China

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Guangzhou, Guangdong, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Shenzhen, Guangdong, China

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Shenzhen, Guangdong, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Liuzhou, Guangxi, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Nanning, Guangxi, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Zunyi, Guizhou, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Haikou, Hainan, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Zhengzhou, Henan, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Wuhan, Hubei, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Changsha, Hunan, China

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Changsha, Hunan, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Changhou, Jiangsu, China

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Zhenjiang, Jiangsu, China

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Nanchang, Jiangxi, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Changchun, Jilin, China

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Shenyang, Liaoning, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Taiyuan, Shanxi, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Xi’an, Shanxi, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Chengdu, Sichuan, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Kunming, Yunnan, China

    Contact Email: •••••@•••••

  • AusperBio Investigational Site

    RECRUITING

    Hangzhou, Zhejiang, China

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

  • AusperBio Investigational Site

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.